CAR-T for multiple myeloma: practice pearls

CAR-T for multiple myeloma: practice pearls

The CAR-T cell products ciltacabtagene autoleucel and idecabtagene vicleucel have transformed the management of patients with multiple myeloma. Here, we present a practical guide highlighting clinical pearls on the incorporation of CAR-T into clinical practice. Topics addressed include expected outcomes, recommendations for referral timing, bridging therapy, treatment complications, therapeutic sequencing, and management of relapse.

New Hope for Myeloma Patients: Karmanos Advances Treatment and Survival

DETROIT - The Barbara Ann Karmanos Cancer Institute is at the forefront of a hopeful trend: rising survival rates and better outcomes for those diagnosed with multiple myeloma, a rare but aggressive cancer of the plasma cells. As one of the leading cancer centers in the Midwest, Karmanos is expanding treatment options and clinical trials that are significantly improving patient prognosis....